| Cat.No. | Name | Information |
|---|---|---|
| M2562 | ZCL278 | ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM. |
| M6282 | NSC 23766 | NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA. |
| M9356 | AMG-510 | AMG-510 (Sotorasib) is a potent KRAS G12C covalent inhibitor. |
| M9428 | MRTX849 (Adagrasib) | MRTX849 (Adagrasib) is a potent, highly selective, oral available KRAS G12C inhibitor. |
| M8999 | CCG-1423 | CCG-1423 is a novel specific inhibitor of RhoA transcriptional signaling. |
| M29868 | ZINC69391 | ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects. |
| M29747 | Fulzerasib | Fulzerasib is a potent KRAS inhibitor that downregulates KRAS protein activation by covalently and irreversibly modifying cysteine residues of the KRAS G12C protein mutant and inhibiting GTP/GDP exchange mediated by the protein. |
| M29707 | Garsorasib | Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential for the research of various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (non-small cell lung cancer). |
| M27747 | AZA1 | AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion. |
| M27640 | KRA-533 | KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells. |
| M25612 | Elironrasib | Elironrasib is an orally active and covalent inhibitor of KRASG12C(ON). Elironrasib prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. Elironrasib inhibits ERK signaling and induced apoptosis in KRASG12C-mutant H358 cells. Elironrasib also inhibits the proliferation of KRASG12C mutant cells with a median IC50 of 0.11 nM. |
| M21533 | BI-0474 | BI-0474 is a covalent KRASG12C inhibitor. The IC50 value for GDP-KRAS::SOS1 protein-protein interaction was 7.0 nM. BI-0474 also showed better antitumor activity in non-small cell lung cancer xenograft models. |
| M21078 | Olomorasib | Olomorasib is a potent inhibitor of KRAS G12C. Olomorasib significantly inhibits tumor growth. |
| M20741 | Antineoplaston A10 | Antineoplaston A10 is a naturally occurring substance in the human body that that can be potentially used for the treatment of glioma, lymphoma, astrocytoma and breast cancer. The main ingredient active of antineoplaston A10 (Phenylacetylglutamine, PG) inhibits RAS and promotes apoptosis. |
| M20013 | MRTX0902 | MRTX0902 is an oral brain penetrating SOS1:KRAS protein-protein interaction inhibitor with an IC50 of 46 nM. |
| M14058 | Y16 | Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM. |
| M14055 | Pan-RAS-IN-1 | Pan-RAS-IN-1 is a pan-Ras inhibitor that disrupts the interaction of Ras proteins and their effectors. |
| M14054 | MRTX-1257 | MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells. |
| M14053 | Deltarasin hydrochloride | Deltarasin hydrochloride is an inhibitor of KRAS-PDEδinteraction with Kd of 38 nM for binding to purified PDEδ. |
| M14052 | CCG-100602 | CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (MRTF-A/SRF) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF. |
| M11442 | Divarasib | Divarasib (GDC-6036) is an orally active, selective, covalently mutated KRAS G12C inhibitor with an IC50<0.01 μM for K-Ras G12C. GDC-6036 has an EC50 of 2 nM in K-Ras G12C-alkylated HCC1171 cells. can be used in studies related to non-small cell lung cancer ( NSCLC) related studies. |
| M11263 | HJC0197 | HJC0197 is a potent antagonist of Epac1 (the exchange protein directly activated by cAMP 1) and Epac2 (IC50=5.9 μM for Epac2). HJC0197 selectively blocked camp-induced Epac activation. HJC0197 inhibited epAC1-mediated RAP1-GDP exchange activity in the presence of isoconcentration of cAMP. |
| M11016 | Opnurasib | Opnurasib (JDQ-443，NVP-JDQ443) is a covalent inhibitor of KRAS G12C. |
| M10978 | Methylophiopogonanone B | Methylophiopogonanone B, high isotinodihydroflavones, extracted from the roots of Wheat Dong, has a high antioxidant capacity. Methylophiopogonanone B increases GTP-Rho and works through the Rho signaling pathway, and Methylophiopogonanone B induces changes in cell morphology, including dendritic contraction and stress fiber formation, through actin cytoskeletal recombination. |
| M10600 | SAH-SOS1A TFA | SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM) and directly and independently blocks nucleotide association. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
